UPC vs. KTTA, HEPA, CANF, EFTR, VCNX, CYCN, PCSA, RNAZ, IBIO, and BNOX
Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Pasithea Therapeutics (KTTA), Hepion Pharmaceuticals (HEPA), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Vaccinex (VCNX), Cyclerion Therapeutics (CYCN), Processa Pharmaceuticals (PCSA), TransCode Therapeutics (RNAZ), iBio (IBIO), and Bionomics (BNOX). These companies are all part of the "pharmaceutical preparations" industry.
Universe Pharmaceuticals (NYSE:UPC) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Pasithea Therapeutics received 2 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
In the previous week, Pasithea Therapeutics had 5 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 5 mentions for Pasithea Therapeutics and 0 mentions for Universe Pharmaceuticals. Pasithea Therapeutics' average media sentiment score of 0.87 beat Universe Pharmaceuticals' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.
Universe Pharmaceuticals has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Universe Pharmaceuticals' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.
Universe Pharmaceuticals has higher revenue and earnings than Pasithea Therapeutics.
Summary
Universe Pharmaceuticals beats Pasithea Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Universe Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Universe Pharmaceuticals Competitors List
Related Companies and Tools
